share_log

Cantor Fitzgerald Initiates Coverage On ARS Pharmaceuticals With Overweight Rating, Announces Price Target of $30

Benzinga ·  Aug 20 17:43  · Ratings

Cantor Fitzgerald analyst Josh Schimmer initiates coverage on ARS Pharmaceuticals (NASDAQ:SPRY) with a Overweight rating and announces Price Target of $30.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment